| Andrew K Nuss, LCMHC | |
|
11 N Main St, Randolph, VT 05060-1126 | |
| (802) 728-4466 | |
| (802) 428-4197 |
| Full Name | Andrew K Nuss |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 11 N Main St, Randolph, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346476561 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 068-0050720 (Vermont) | Primary |
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 000521 (Vermont) | Secondary |
| Entity Name | Clara Martin Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386710861 PECOS PAC ID: 1951395367 Enrollment ID: O20060315000608 |
News Archive
In their article "Over 30 million psychedelic users in the United States", Teri S Krebs and P-l-rjan Johansen from the Department of Neuroscience at Norwegian University of Science and Technology, use data from a randomly-selected sample of over 57,000 individuals surveyed for the 2010 National Survey on Drug Use and Health, to estimate lifetime prevalence of psychedelic use.
Eating out, lack of social support and high-risk lifestyles are just some of the barriers that stop patients with type 2 diabetes from controlling their condition, according to a research review that covered 8,900 patients and 4,550 healthcare providers from 28 countries.
Abbott today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted that, for symptomatic and asymptomatic carotid artery disease patients at standard surgical risk, there is reasonable assurance that the benefits of the RX ACCULINK® Carotid Stent System outweigh its risks (Yes: 7, No: 3, Abstain: 1).
AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.
A new report from UnitedHealth Group Inc. takes aim at the way U.S. doctors get paid, saying the nation could save up to $1 trillion over the next decade in health care costs if it were possible to "unleash the potential of payment reform initiatives."
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew K Nuss, LCMHC 11 N Main St, Randolph, VT 05060-1126 Ph: (802) 728-4466 | Andrew K Nuss, LCMHC 11 N Main St, Randolph, VT 05060-1126 Ph: (802) 728-4466 |
News Archive
In their article "Over 30 million psychedelic users in the United States", Teri S Krebs and P-l-rjan Johansen from the Department of Neuroscience at Norwegian University of Science and Technology, use data from a randomly-selected sample of over 57,000 individuals surveyed for the 2010 National Survey on Drug Use and Health, to estimate lifetime prevalence of psychedelic use.
Eating out, lack of social support and high-risk lifestyles are just some of the barriers that stop patients with type 2 diabetes from controlling their condition, according to a research review that covered 8,900 patients and 4,550 healthcare providers from 28 countries.
Abbott today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted that, for symptomatic and asymptomatic carotid artery disease patients at standard surgical risk, there is reasonable assurance that the benefits of the RX ACCULINK® Carotid Stent System outweigh its risks (Yes: 7, No: 3, Abstain: 1).
AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.
A new report from UnitedHealth Group Inc. takes aim at the way U.S. doctors get paid, saying the nation could save up to $1 trillion over the next decade in health care costs if it were possible to "unleash the potential of payment reform initiatives."
› Verified 7 days ago
Renee Weeks, LCMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 S Main St, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 | |
David Pellegrino, LCMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 S Main St, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 | |
Jessica Schupp, LCMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 Main Street, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 | |
Howard Hood, LCMHC Counselor Medicare: Medicare Enrolled Practice Location: 11 S Main St, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 | |
Adam Bindrum, Counselor Medicare: Medicare Enrolled Practice Location: 11 N Main St, Randolph, VT 05060 Phone: 802-728-4466 | |
Kara Rebecca Toms, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 N Main St, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 | |
Kerrie Taylor, LCMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 S Main St, Randolph, VT 05060 Phone: 802-728-4466 Fax: 802-728-4197 |